"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy ...

Looking at the data from clinical trials of new GLP-1 agonists, it's clear that patients will need to stay on the drugs to ...

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Fueled by the rise of the blockbuster GLP-1 drugs, including Ozempic and Wegovy, thinness appears to be making a comeback in ...

Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...